BOCA RATON, Fla.–(BUSINESS WIRE)–Dec. 19, 2017– TherapeuticsMD, Inc. (NASDAQ:TXMD), an innovative women’s healthcare company, today announced the acceptance of the New Drug Application (NDA) resubmission for TX-004HR, the company’s…Original Article
TherapeuticsMD Announces FDA Acceptance of New Drug Application and Prescription Drug User Fee Act (PDUFA) Date for TX-004HR
